Everything below concerns lipodystrophy. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-08. Numbers and descriptions here follow the published literature rather than marketing material.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
In addition to drug crops, it is also not uncommon for drug farms to also host livestock, both to have a legal source of revenue to help disguise the dirty money and so that the livestock can provide a source of organic fertilizer (such as manure) for the drug crops. There are multiple instances where traffickers set up some of their drug farms, safe houses and drug labs in remote wilderness areas. Once produced, the fully processed narcotics are then transported to more populated areas to be sold. Oftentimes the traffickers stationed in these remote criminal settlements, sustain themselves with a combination of survival skills and with food, supplies and workers being brought to them by associates. The reason that traffickers have been known to establish such remote compounds is so that the surrounding area can help to provide varying degrees of natural cover. Additionally the traffickers may also hope, that the surrounding terrain and local wildlife might serve to deter or impede either investigative authorities or rival gangs if the location of the clandestine compound were revealed. While usually thought of as an urban issue, drug trafficking is also known to be a problem in both suburban and rural areas as well.
== Contraindications == The only absolute contraindication to the use of ivermectin is hypersensitivity to the active ingredient or any component of the formulation. In children under the age of five or those who weigh less than 15 kilograms (33 pounds), there is limited data regarding the efficacy or safety of ivermectin, though the available data demonstrate few adverse effects. However, the American Academy of Pediatrics cautions against use of ivermectin in such patients, as the blood–brain barrier is less developed, and thus there may be an increased risk of particular CNS side effects such as encephalopathy, ataxia, coma, or death. The American Academy of Family Physicians also recommends against use in these patients, given a lack of sufficient data to prove drug safety. Ivermectin is secreted in very low concentration in breast milk. It remains unclear if ivermectin is safe during pregnancy.
=== Differences with the government === Heseltine's resignation in January 1986 had been just before the only occasion on which the Poll Tax was discussed in Cabinet. He spoke against the tax when it was enacted into law in 1987–1988, but abstained rather than voting against as Edward Heath did, although he voted for Michael Mates' amendment which tried to introduce an element of banding according to ability to pay. Heseltine remained aloof from factional plotting in the Commons, and voted with the left-wing Lollard faction in backbench committee elections. Heseltine later said that he regretted resigning from the Cabinet in 1986, as he subsequently often wondered if he and Nigel Lawson might have been able to persuade Thatcher to abandon the tax. Heseltine clashed bitterly at this time with his former friend Nicholas Ridley. Ridley was a Eurosceptic, a free marketer, a champion of the poll tax and a key ally of Thatcher. Heseltine argued that there was too much green belt building (although in fact only slightly more so than he had himself authorised as Environment Secretary) and stated that as a property developer he had never built on a "green" site, forgetting that he had done so in Tenterden in the early 1960s.
Sources: en.wikipedia.org
Since radon is a colorless, odorless gas, the only way to know how much is present in the air or water is to perform tests. In the US, radon test kits are available to the public at retail stores, such as hardware stores, for home use, and testing is available through licensed professionals, who are often home inspectors. Efforts to reduce indoor radon levels are called radon mitigation. In the US, the EPA recommends all houses be tested for radon. In the UK, under the Housing Health & Safety Rating System, property owners have an obligation to evaluate potential risks and hazards to health and safety in a residential property. Alpha-radiation monitoring over the long term is a method of testing for radon that is more common in countries outside the United States.
=== February === 3 February – Prime Minister Keir Starmer rejects an allegation that he broke COVID-19 regulations by having a voice coach present at a press conference where he responded to a Brexit deal negotiated by Boris Johnson. For the first time, Reform UK have led an opinion poll, after coming top with 25% in a YouGov poll for Sky News. Labour are second on 24%, with the Conservatives on 21%. Northern Ireland's Economy Minister, Conor Murphy steps down from the post and announces he will leave Stormont after being elected to the Irish Seanad. Caoimhe Archibald is appointed to replace him as Economy Minister. 4 February – BBC News reports that Jack Lopresti, the former Conservative MP for Filton and Bradley Stoke who lost the seat at the last general election has joined the Ukrainian military. Welsh Conservatives leader Darren Millar and his colleague Russell George miss a Senedd vote on the Eluned Morgan government's budget for 2025–26 because they have travelled to the United States for the annual National Prayer Breakfast. 5 February – Deputy Prime Minister Angela Rayner confirms that local elections in East Sussex, West Sussex, Essex, Thurrock, Hampshire, the Isle of Wight, Norfolk, Suffolk and Surrey will be delayed for a year to allow major local government reorganisations to take place. Four of the seven MPs suspended from the Labour Party for voting against the child benefit cap are readmitted to the party; they are Richard Burgon, Ian Byrne, Imran Hussain and Rebecca Long-Bailey.
==== 1935–1949 ==== Teva Pharmaceutical Industries took its present form through the efforts of Günther Friedländer and his aunt Else Kober on May 1, 1935. The original registration was under the name Teva Middle East Pharmaceutical & Chemical Works Co. Ltd. in Jerusalem, then part of Mandatory Palestine. Friedländer was a German pharmacist, botanist and pharmacognosist, who immigrated to Mandatory Palestine in 1934. The company was built with an investment of £4,900, which came from the family's own capital and partly from loans from other German immigrants. Capital shortage led to the joining of the banker Alfred Feuchtwanger as a partner in Teva, who received 33% of the shares in return for his investment. Friedländer's business philosophy opined that the pharmaceutical industry has a reliable basis in difficult economic times, since "A Jewish mother will always buy medicine for her children". In the Second World War, the company provided medicine to the allied forces and in particular to the British army present in the Middle East. After the war, Sir Alan Gordon Cunningham, the last of the High Commissioners for Palestine and Transjordan, visited Teva on behalf of the Secretary of State for the Colonies. His visit promoted Teva's reputation in the pharmaceutical market and created a momentum for Teva's development. During Mandatory Palestine, Teva exported its medical products to Arab countries. In 1941, Friedländer presented Teva products in an exhibition held in Cairo, Egypt.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.